Furthermore, we evaluated 10 immunogram scores for gliomas with different TNFSF13 expression level (Figure 3B), and the results indicated that high TNFSF13 cohort appeared higher scores in nine immunogram terms than low TNFSF13 cohort, and nine terms included glycolysis, innate immunity, priming activation, T cells, interferon γ (IFNG) response, inhibitory molecules, inhibitory cells Tregs (regulatory T cells), inhibitory cells MDSCs (myeloid-derived suppressor cells), and recognition of tumor cells. The gene discussed is TNFSF13; the disease is neoplasm.